VCYT
HEALTHCAREVeracyte Inc
AI Insight
What's Moving VCYT Today?
No stock-specific AI insight has been generated for VCYT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$22.61$54.72
$53.79
Fundamentals
Market Cap$4.2B
P/E Ratio49.3
EPS$1.08
Dividend Yield—
Dividend / Share—
ROE6.9%
Profit Margin16.3%
Debt / Equity—
Trading
Volume845K
Avg Volume (10D)—
Shares Outstanding79.8M
VCYT News
25 articles- Veracyte (VCYT) director logs 3,729-share Rule 10b5-1 stock saleStock Titan·Jun 23, 2026
- This Top Stock Has Surged. CEO Explains Key To Veracyte's Success.Yahoo Finance·Jun 18, 2026
- Dow Jones Futures: Techs Rebound, SpaceX Rises Despite Trump's Iran Threat; Warsh's Fed Debut DueYahoo Finance·Jun 17, 2026
- Director at Veracyte (VCYT) receives grant of 5,272 restricted stock unitsStock Titan·Jun 16, 2026
- Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth TodayYahoo Finance·Jun 10, 2026
- How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst CallYahoo Finance·Jun 4, 2026
- Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?Yahoo Finance·Jun 4, 2026
- Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.Yahoo Finance·Jun 1, 2026
- ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate CancerYahoo Finance·May 30, 2026
- Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid ChemotherapyYahoo Finance·May 29, 2026
- Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?Yahoo Finance·May 27, 2026
- Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?Yahoo Finance·May 25, 2026
- Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade AgoYahoo Finance·May 25, 2026
- Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer TestsYahoo Finance·May 23, 2026
- Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO FindingsYahoo Finance·May 22, 2026
- OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast CancerYahoo Finance·May 21, 2026
- Veracyte stock (US92347M1009): diagnostics specialist back in the spotlight after new data and indexAD HOC NEWS·May 20, 2026
- Veracyte to Participate in Upcoming Investor ConferencesYahoo Finance·May 19, 2026
- Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder CancerYahoo Finance·May 15, 2026
- Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings AreYahoo Finance·May 14, 2026
- Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer StudiesSimply Wall Street·May 9, 2026
- Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 planStock Titan·May 8, 2026
- Why Veracyte Stock Is Skyrocketing Higher This WeekMotley Fool·May 8, 2026
- Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextYahoo Finance·May 7, 2026
- Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for InvestorsYahoo Finance·May 7, 2026
All 25 articles loaded
Price Data
Open$52.79
Previous Close$53.79
Day High$54.12
Day Low$52.65
52 Week High$54.72
52 Week Low$22.61
52-Week Range
$22.61$54.72
$53.79
Fundamentals
Market Cap$4.2B
P/E Ratio49.3
EPS$1.08
Dividend Yield—
Dividend / Share—
ROE6.9%
Profit Margin16.3%
Debt / Equity—
Trading
Volume845K
Avg Volume (10D)—
Shares Outstanding79.8M
About Veracyte Inc
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—